Stay updated on Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check24 days agoChange DetectedA notice was added stating that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference0.5%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer release label changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check38 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check59 days agoChange DetectedThe record history now shows the latest revision as v3.7.0, replacing the previous v3.6.6 label, indicating an update to how the history is versioned or displayed.SummaryDifference0.1%

- Check66 days agoChange DetectedNo additions or deletions are listed for this study history page in the provided data. Consequently, there are no content changes to describe.SummaryDifference0.1%

Stay in the know with updates to Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.